UPF
9.9.2021 17:53:11 CEST | Business Wire | Press release
A wide range of challenges stand in the way of building a stable and relatively peaceful global order for the 21st Century. Recent events related to the U.S. withdrawal from Afghanistan underscore this fact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005818/en/
Of critical importance to the geopolitical dynamics of our time is the ongoing crisis on the Korean Peninsula, which impacts East Asia and the rest of the world. While efforts toward peace have prevented another war in Northeast Asia, the potential for conflict still remains and would involve the U.S., China, Russia, and Japan. It is time for a new strategy to move toward reconciliation and cooperation on the Korean Peninsula.
Who: Think Tank 2022 Rally of Hope online is sponsored by the Universal Peace Federation (upf.org)
When: Sunday, September 12, 2021, 2:30 a.m. CET, Europe & Middle East (Live broadcast from South Korea) or Replay/Highlights: September 12, 2021, 6:00 PM CET
Where : Join the Live Event September 12th, at 02:30 AM (CET)
through this link: https://www.peacelink.live/online/
Join the Highlight Event September 12th, at 06:00 PM (CET)
through Zoom link: http://www.zoom.rallyofhope.eu/
or Live Facebook: http://www.facebook.rallyofhope.eu/
What: Inaugurated in 2020, the Rally of Hope is a series of live-streamed online productions using advanced augmented reality technology to connect millions of global viewers. Featuring prominent world leaders and captivating entertainment, the Rally of Hope is uplifting, actionable and faith-based.
Why: This new and unique program empowers the ordinary citizen who seeks meaningful change in their personal life, family, community, and even globally, by participating in a movement which transcends political, religious, racial, and ideological boundaries.
Previous Rallies of Hope have provided a platform for top experts to speak about the complex issues facing our planet, including: climate change, geopolitical hotspots, challenges of the coronavirus pandemic, honoring veterans of the Korean War on its 70th anniversary, the role of faith in peacebuilding, and much more.
The theme of the Think Tank 2022 Rally of Hope is “Steps Toward Peace in Asia: Focus on Reconciliation and Cooperation on the Korean Peninsula.” Although the Armistice Agreement brought an end to the hostilities, the Korean Peninsula continues to be a “storm center” for peace and security in the region. World leaders will speak about the risks and opportunities of resolving issues on the Korean Peninsula and steps toward peace in Asia.
Keynote Speakers : Kingdom of Cambodia Prime Minister Hun Sen , European Commission President
José Manuel Barroso (2004-2014), Republic of the Philippines President Gloria Macapagal Arroyo (2000-2010), Republic of India Prime Minister H.D. Deve Gowda (1996-1997), Trinidad and Tobago President Anthony Thomas Aquinas Carmona (2013-2018), and Republic of Serbia President Nataša Mićić (2002-2004). UPF Co-Founder Hak Ja Han Moon will offer a special message of hope in her Founder’s Address .
Find out more about the Rally of Hope & Think Tank 2022 here: https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005818/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom